

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACE INHIBITORS <i>Effective 10/2/06</i>	ACE INHIBITORS		Four of the preferred agents must be tried for at least 30 days each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ACEON (perindopril) ALTACE (ramipril) benazepril captopril enalapril lisinopril MAVIK (trandolapril)	ACCUPRIL (quinapril) CAPOTEN (captopril) fosinopril LOTENSIN (benazepril) moexepiril MONOPRIL (fosinopril) PRINIVIL (lisinopril) quinapril UNIVASC (moexepiril) VASOTEC (enalapril) ZESTRIL (lisinopril)	
	ACE INHIBITOR/DIURETIC COMBINATIONS		
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ lisinopril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) fosinopril/HCTZ LOTENSIN HCT (benazepril/HCTZ) MONOPRIL HCT (fosinopril/HCTZ) PRINZIDE (lisinopril/HCTZ) quinapril/HCTZ UNIRETIC (moexepiril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS <i>Effective 4/2/07</i>	LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil)	LEXXEL (enalapril/felodipine)	Each of the preferred agents must be tried for at least two weeks each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients starting therapy in this class must show a documented allergy to the preferred agents before a non-preferred agent will be authorized.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL - Requires Clinical PA

NR - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

ACNE AGENTS, TOPICAL <i>Effective 4/2/07</i>	ANTIBIOTICS		A trial of 30 days of one of the preferred agents in each category will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.) PA required after 17 years of age for tretinoin products.
	AKNE-MYCIN (erythromycin) clindamycin erythromycin	CLINDAGEL (clindamycin) EVOCLIN (clindamycin)	
	RETINOIDS		
	RETIN-A MICRO (tretinoin) ^{CL} TAZORAC (tazarotene) tretinoin ^{CL}	DIFFERIN (adapalene)	
ALZHEIMER'S AGENTS <i>Effective 10/2/06</i>	OTHERS		A trial of a preferred agent will be required before a non-preferred agent In this class will be authorized. Current prescriptions for Razadyne and Razadyne ER will be grandfathered..
	AZELEX (azelaic acid) BENZACLIN (benzoyl peroxide/clindamycin) benzoyl peroxide CLINAC BPO (benzoyl peroxide) DUAC (benzoyl peroxide/ clindamycin)	BENZAMYCIN PAK (benzoyl peroxide/erythromycin) BENZIQ (benzoyl peroxide) BREVOXYL (benzoyl peroxide) erythromycin/benzoyl peroxide INOVA (benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/ salicylic acid) KLARON (sodium sulfacetamide) NEOBENZ MICRO (benzoyl peroxide) NUOX (benzoyl peroxide/sulfur) SULFOXYL (benzoyl peroxide/sulfur) TRIAZ (benzoyl peroxide) ZACLIR (benzoyl peroxide) ZODERM (benzoyl peroxide)	
ALZHEIMER'S AGENTS <i>Effective 10/2/06</i>	CHOLINESTERASE INHIBITORS		A trial of a preferred agent will be required before a non-preferred agent In this class will be authorized. Current prescriptions for Razadyne and Razadyne ER will be grandfathered..
	ARICEPT (donepezil) EXELON (rivastigmine)	COGNEX (tacrine) RAZADYNE (galantamine) RAZADYNE ER (galantamine)	
	NMDA RECEPTOR ANTAGONIST		
	NAMENDA (memantine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

<p>ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral)</p> <p><i>Effective 4/2/07</i></p>	<p>APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP tramadol tramadol/APAP</p>	<p>ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine COMBUNOX (oxycodone/ibuprofen) DARVOCET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET, LORTAB (hydrocodone/APAP) meperidine OPANA (oxymorphone) OXYFAST, OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen)</p>	<p>Three of the preferred agents must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy.</p> <p>Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization and review by the Medical Director.</p>
<p>ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)</p>	<p>DURAGESIC (fentanyl) KADIAN (morphine) methadone morphine SR</p>	<p>AVINZA (morphine) fentanyl MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol)</p>	<p>Three preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.</p>

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

ANDROGENIC AGENTS <i>Effective 10/2/06</i>	ANDRODERM (testosterone) ANDROGEL (testosterone)	TESTIM (testosterone)	The non-preferred agents will be approved only if one of the exceptions on the PA form is present.																
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) <i>Effective 4/2/07</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">ANGIOTENSIN RECEPTOR BLOCKERS</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan) </td> <td style="width: 50%; vertical-align: top;"> ATACAND (candesartan) TEVETEN (eprosartan) </td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">ARB/DIURETIC COMBINATIONS</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) </td> <td style="width: 50%; vertical-align: top;"> ATACAND-HCT (candesartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ) </td> </tr> </table>		ANGIOTENSIN RECEPTOR BLOCKERS		AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)	ARB/DIURETIC COMBINATIONS		AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ)	Each of the preferred agents in the corresponding group must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.								
ANGIOTENSIN RECEPTOR BLOCKERS																			
AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)																		
ARB/DIURETIC COMBINATIONS																			
AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ)																		
ANTICOAGULANTS, INJECTABLE^{CL} <i>Effective 4/2/07</i>	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	INNOHEP (tinzaparin)	A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.																
ANTICONVULSANTS <i>Effective 4/2/07</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">BARBITURATES</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> mephobarbital phenobarbital primidone </td> <td style="width: 50%; vertical-align: top;"> MEBARAL (mephobarbital) MYSOLINE (primidone) </td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">HYDANTOINS</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> PEGANONE (ethotoin) phenytoin </td> <td style="width: 50%; vertical-align: top;"> DILANTIN (phenytoin) PHENYTEK (phenytoin) </td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">SUCCINIMIDES</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> CELONTIN (methsuximide) ethosuximide </td> <td style="width: 50%; vertical-align: top;"> ZARONTIN (ethosuximide) </td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">BENZODIAZEPINES</th> </tr> <tr> <td style="width: 50%; vertical-align: top;"> clonazepam DIASTAT (diazepam rectal) diazepam </td> <td style="width: 50%; vertical-align: top;"> KLONOPIN (clonazepam) </td> </tr> </table>		BARBITURATES		mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	HYDANTOINS		PEGANONE (ethotoin) phenytoin	DILANTIN (phenytoin) PHENYTEK (phenytoin)	SUCCINIMIDES		CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)	BENZODIAZEPINES		clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)	Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Patients stabilized on non-preferred agents will receive authorization to continue these drugs. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present.
BARBITURATES																			
mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)																		
HYDANTOINS																			
PEGANONE (ethotoin) phenytoin	DILANTIN (phenytoin) PHENYTEK (phenytoin)																		
SUCCINIMIDES																			
CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)																		
BENZODIAZEPINES																			
clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)																		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

		ADJUVANTS	
	carbamazepine CARBATROL (carbamazepine) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) EQUETRO (carbamazepine) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin) TOPAMAX (topiramate) TRILEPTAL (oxcarbazepine) valproic acid zonisamide	DEPAKENE (valproic acid) NEURONTIN (gabapentin) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide)	Lyrica requires a 30-day trial of gabapentin for treatment naïve patients.
ANTIDEPRESSANTS, OTHER (second generation, non-SSRI) <i>Effective 4/2/07</i>	bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone	bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone REMERON (mirtazapine) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)	A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present. Patients on a non-preferred agent will be authorized to continue on that agent.
ANTIDEPRESSANTS, SSRIs <i>Effective 10/2/06</i>	citalopram fluoxetine fluvoxamine LEXAPRO (escitalopram) paroxetine PAXIL CR (paroxetine) PEXEVA (paroxetine) ZOLOFT (sertraline)	CELEXA (citalopram) PAXIL (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) sertraline	None of the non-preferred dosage forms will be authorized unless there is documentation showing that the preferred dosage forms of the corresponding agents are inappropriate for the patient.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

ANTIEMETICS, ORAL <i>Effective 10/2/06</i>	5HT3 RECEPTOR BLOCKERS		A trial of Zofran is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Quantity limits for Zofran - 14 tablets per 21 days; in cases of hyperemesis during pregnancy, increased quantities may be authorized.
	ZOFRAN (ondansetron) ZOFRAN ODT (ondansetron)	ANZEMET (dolasetron) KYTRIL (granisetron) ondansetron	
	SUBSTANCE P ANTAGONISTS		
	EMEND (aprepitant)		Quantity limits for Emend - 12 tablets per 28 days
ANTIFUNGALS, ORAL <i>Effective 10/2/06</i>	clotrimazole fluconazole ketoconazole ^{CL} LAMISIL (terbinafine) ^{CL} MYCOSTATIN Pastilles (nystatin) nystatin	ANCOBON (flucytosine) DIFLUCAN (fluconazole) GRIFULVIN V (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) SPORANOX (itraconazole) VFEND (voriconazole)	Non-preferred agents will be approved only if one of the exceptions on the PA form is present. PA is required when limits are exceeded. PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis
	ANTIFUNGALS		Three of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
ANTIFUNGALS, TOPICAL <i>Effective 10/2/06</i>	econazole EXELDERM (sulconazole) ketoconazole NAFTIN (naftifine) nystatin	ciclopirox ERTACZO (sertaconazole) LOPROX (ciclopirox) MENTAX (butenafine) MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide)	
	ANTIFUNGAL/STEROID COMBINATIONS		
	clotrimazole/betamethasone nystatin/triamcinolone	LOTTRISONE (clotrimazole/betamethasone) MYCOLOG (nystatin/triamcinolone)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

ANTIHISTAMINES, MINIMALLY SEDATING <i>Effective 4/2/07</i>	ANTIHISTAMINES		A preferred agent, in the age appropriate dosage form, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALAVERT (loratadine) CLARINEX Syrup (desloratadine) loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARITIN (loratadine) fexofenadine ZYRTEC (cetirizine)	
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
	ALAVERT-D (loratadine/pseudoephedrine) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (cetirizine/pseudoephedrine)	
ANTIMIGRAINE AGENTS, TRIPTANS <i>Effective 4/2/07</i>	AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAX (eletriptan)	AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class.
ANTIPARKINSON'S AGENTS (Oral) <i>Effective 10/2/06</i>	ANTICHOLINERGICS		Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents before a non-preferred agent will be authorized.
	benztropine KEMADRIN (procyclidine) trihexyphenidyl	COGENTIN (benztropine)	
	COMT INHIBITORS		
	COMTAN (entacapone)	TASMAR (tolcapone)	
	DOPAMINE AGONISTS		
	MIRAPEX (pramipexole) REQUIP (ropinirole)	pergolide PERMAX (pergolide)	
OTHER ANTIPARKINSON'S AGENTS			
carbidopa/levodopa selegiline STALEVO (levodopa/carbidopa/entacapone)	AZILECT (rasagiline) ^{NR} ELDEPRYL (selegiline) PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline) ^{NR}		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

ANTIPSYCHOTICS, ATYPICAL (Oral) Effective 10/2/06	ORAL		Upon discharge, hospitalized patients stabilized on non-preferred agents will receive authorization to continue these drugs. New patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present.
	clozapine FAZACLO (clozapine) GEODON (ziprasidone) RISPERDAL (risperidone) SEROQUEL (quetiapine)	ABILIFY (aripiprazole) CLOZARIL (clozapine) ZYPREXA (olanzapine)	
	ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS		
		SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral) Effective 10/2/06	acyclovir amantadine ganciclovir VALCYTE (valganciclovir) VALTREX (valacyclovir)	CYTOVENE (ganciclovir) FAMVIR (famciclovir) FLUMADINE (rimantadine) rimantadine RELENZA (zanamivir) SYMMETREL (amantadine) TAMIFLU (oseltamivir) ZOVIRAX (acyclovir)	All of the appropriate preferred agents with the applicable indication must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
ATOPIC DERMATITIS Effective 10/2/06	ELIDEL (pimecrolimus) PROTOPIC (tacrolimus)		
BETA BLOCKERS (Oral) Effective 4/2/07	BETA BLOCKERS		If one of the exceptions on the PA form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved.
	acebutolol atenolol betaxolol bisoprolol INDERAL LA (propranolol) metoprolol nadolol pindolol propranolol sotalol timolol TOPROL XL (metoprolol)	BETAPACE (sotalol) BLOCADREN (timolol) CARTROL (carteolol) CORGARD (nadolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) ZEBETA (bisoprolol)	
	BETA- AND ALPHA- BLOCKERS		
	COREG (carvedilol) labetalol	COREG CR (carvedilol) ^{NR} TRANDATE (labetalol)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

BLADDER RELAXANT PREPARATIONS <i>Effective 4/2/07</i>	DITROPAN XL (oxybutynin) ENABLEX (darifenacin) oxybutynin OXYTROL (oxybutynin) SANCTURA (trospium) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin)	All of the preferred agents in the class must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.																
BONE RESORPTION SUPPRESSION AND RELATED AGENTS <i>Effective 10/2/06</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">BISPHOSPHONATES</th> </tr> <tr> <td style="width: 50%;">FOSAMAX (alendronate)</td> <td style="width: 50%;">ACTONEL (risedronate)</td> </tr> <tr> <td>FOSAMAX PLUS D (alendronate/vitamin D)</td> <td>ACTONEL WITH CALCIUM (risedronate/calcium)</td> </tr> <tr> <td></td> <td>BONIVA (ibandronate)</td> </tr> <tr> <td></td> <td>DIDRONEL (etidronate)</td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS</th> </tr> <tr> <td>EVISTA (raloxifene)</td> <td>FORTEO (teriparatide)</td> </tr> <tr> <td>MIACALCIN (calcitonin)</td> <td>FORTICAL (calcitonin)</td> </tr> </table>		BISPHOSPHONATES		FOSAMAX (alendronate)	ACTONEL (risedronate)	FOSAMAX PLUS D (alendronate/vitamin D)	ACTONEL WITH CALCIUM (risedronate/calcium)		BONIVA (ibandronate)		DIDRONEL (etidronate)	OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS		EVISTA (raloxifene)	FORTEO (teriparatide)	MIACALCIN (calcitonin)	FORTICAL (calcitonin)	One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
BISPHOSPHONATES																			
FOSAMAX (alendronate)	ACTONEL (risedronate)																		
FOSAMAX PLUS D (alendronate/vitamin D)	ACTONEL WITH CALCIUM (risedronate/calcium)																		
	BONIVA (ibandronate)																		
	DIDRONEL (etidronate)																		
OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS																			
EVISTA (raloxifene)	FORTEO (teriparatide)																		
MIACALCIN (calcitonin)	FORTICAL (calcitonin)																		
BPH AGENTS <i>Effective 4/2/07</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">ALPHA BLOCKERS</th> </tr> <tr> <td style="width: 50%;">doxazosin</td> <td style="width: 50%;">CARDURA (doxazosin)</td> </tr> <tr> <td>FLOMAX (tamsulosin)</td> <td>CARDURA XL (doxazosin)</td> </tr> <tr> <td>trazosin</td> <td>HYTRIN (terazosin)</td> </tr> <tr> <td>UROXATRAL (alfuzosin)</td> <td></td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">5-ALPHA-REDUCTASE (5AR) INHIBITORS</th> </tr> <tr> <td>AVODART (dutasteride)</td> <td>finasteride</td> </tr> <tr> <td></td> <td>PROSCAR (finasteride)</td> </tr> </table>		ALPHA BLOCKERS		doxazosin	CARDURA (doxazosin)	FLOMAX (tamsulosin)	CARDURA XL (doxazosin)	trazosin	HYTRIN (terazosin)	UROXATRAL (alfuzosin)		5-ALPHA-REDUCTASE (5AR) INHIBITORS		AVODART (dutasteride)	finasteride		PROSCAR (finasteride)	One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
ALPHA BLOCKERS																			
doxazosin	CARDURA (doxazosin)																		
FLOMAX (tamsulosin)	CARDURA XL (doxazosin)																		
trazosin	HYTRIN (terazosin)																		
UROXATRAL (alfuzosin)																			
5-ALPHA-REDUCTASE (5AR) INHIBITORS																			
AVODART (dutasteride)	finasteride																		
	PROSCAR (finasteride)																		
BRONCHODILATORS, ANTICHOLINERGIC <i>Effective 10/2/06</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">ANTICHOLINERGIC</th> </tr> <tr> <td style="width: 50%;">ATROVENT HFA (ipratropium)</td> <td style="width: 50%;">ATROVENT Inhalation Solution (ipratropium)</td> </tr> <tr> <td>ipratropium</td> <td></td> </tr> <tr> <td>SPIRIVA (tiotropium)</td> <td></td> </tr> <tr> <th colspan="2" style="text-align: center; background-color: #cccccc;">ANTICHOLINERGIC-BETA AGONIST COMBINATIONS</th> </tr> <tr> <td>COMBIVENT (albuterol/ipratropium)</td> <td>DUONEB (albuterol/ipratropium)</td> </tr> </table>		ANTICHOLINERGIC		ATROVENT HFA (ipratropium)	ATROVENT Inhalation Solution (ipratropium)	ipratropium		SPIRIVA (tiotropium)		ANTICHOLINERGIC-BETA AGONIST COMBINATIONS		COMBIVENT (albuterol/ipratropium)	DUONEB (albuterol/ipratropium)	The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. For severely compromised patients, DuoNeb will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.				
ANTICHOLINERGIC																			
ATROVENT HFA (ipratropium)	ATROVENT Inhalation Solution (ipratropium)																		
ipratropium																			
SPIRIVA (tiotropium)																			
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS																			
COMBIVENT (albuterol/ipratropium)	DUONEB (albuterol/ipratropium)																		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

BRONCHODILATORS, BETA AGONIST <i>Effective 10/2/06</i>	INHALERS, SHORT-ACTING		<p>All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.</p> <p>Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for a concurrent diagnosis of heart disease.</p> <p>**No PA is required for ACCUNEB for children up to 5 years of age.</p>
	albuterol CFC MAXAIR (pirbuterol) XOPENEX HFA (levalbuterol)	ALUPENT (metaproterenol) PROAIR HFA (albuterol) PROVENTIL (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol)	
	INHALERS, LONG-ACTING		
	FORADIL (formoterol)	SEREVENT (salmeterol)	
	INHALATION SOLUTION		
	albuterol	ACCUNEB (albuterol)** metaproterenol PROVENTIL (albuterol) XOPENEX (levalbuterol)	
ORAL			
albuterol terbutaline	BRETHINE (terbutaline) metaproterenol VOSPIRE ER (albuterol)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

CALCIUM CHANNEL BLOCKERS (Oral) <i>Effective 4/2/07</i>	SHORT-ACTING		One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Nimodipine will be approved with the appropriate diagnosis.
	diltiazem verapamil	ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)	
	LONG-ACTING		
	CARDIZEM LA (diltiazem) diltiazem DYNACIRC CR (isradipine) felodipine nifedipine SULAR (nisoldipine) verapamil VERELAN PM (verapamil)	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM SR (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) TIAZAC (diltiazem) VERELAN (verapamil)	
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral) <i>Effective 10/2/06</i>	BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	amoxicillin/clavulanate AUGMENTIN XR (amoxicillin/clavulanate)	AUGMENTIN (amoxicillin/clavulanate) AUGMENTIN ES-600 (amoxicillin/clavulanate)	
	CEPHALOSPORINS		
	CEDAX (ceftibuten) cefaclor cefadroxil cefprozil cefuroxime cephalixin OMNICEF (cefdinir) SPECTRACEF (cefditoren) SUPRAX (cefixime)	CECLOR (cefaclor) cefpodoxime CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) PANIXINE (cephalexin) RANICLOR (cefaclor) VANTIN (cefpodoxime)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

CYTOKINE & CAM ANTAGONISTS^{CL} <i>Effective 10/2/06</i>	ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) RAPTIVA (efalizumab)		
ERYTHROPOIESIS STIMULATING PROTEINS^{CL} <i>Effective 4/2/07</i>	ARANESP (darbepoetin) PROCRT (rHuEPO)	EPOGEN (rHuEPO)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
FLUROQUINOLONES, ORAL <i>Effective 10/2/06</i>	AVELOX (moxifloxacin) ciprofloxacin CIPRO (ciprofloxacin) Suspension FACTIVE (gemifloxacin)	CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FLOXIN (ofloxacin) LEVAQUIN (levofloxacin) ofloxacin PROQUIN XR (ciprofloxacin)	One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
GLUCOCORTICIDS, INHALED <i>Effective 10/2/06</i>	GLUCOCORTICIDS		All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. Flovent HFA will not require a PA for children through age 6.
	AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) QVAR (beclomethasone)	FLOVENT HFA (fluticasone) PULMICORT (budesonide)	
	GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS		
GROWTH HORMONE^{CL} <i>Effective 4/2/07</i>	GENOTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin)	HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) ZORBTIVE (somatropin)	The preferred agents with the exception of Saizen must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent.
HEPATITIS C TREATMENTS^{CL} <i>Effective 4/2/07</i>	PEGASYS (pegylated interferon) ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) REBETOL (ribavirin)	Patients already on a non-preferred interferon will receive authorization to continue therapy on that agent. Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

HYPOGLYCEMICS, INSULINS AND RELATED AGENTS <i>Effective 10/2/06</i>	INSULIN		To receive authorization for Exubera, patients must meet the following criteria: <ol style="list-style-type: none"> be 18 years or older; have no history of smoking in the past six months; have no history of chronic lung disease in the past two years or presence of acute lower respiratory lung infection; have a base line spirometry to measure FEV1. For renewal, spirometry to measure FEV1 six months after treatment initiation and then annually from second FEV1 measure; have a diagnosis of Type 1 diabetes (stated or inferred) with concomitant use of a longer acting insulin; <p align="center">OR</p> have a diagnosis of Type 2 diabetes (stated or inferred) and maximization of dosage of at least one available oral agent (sulfonylurea, metformin or thiazolidinediones), unless contraindicated; Diagnosis of lipodystrophy or needle phobia that prevents self-injection or injection by a caregiver. To receive authorization for Apidra, patients must meet the following criteria: <ol style="list-style-type: none"> be 18 years or older; be currently on a regimen including a longer-acting or basal insulin. have had a trial of a similar preferred agent, Novolog or Humulin, with documentation that the desired results were not achieved.
	HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) HUMULIN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) EXUBERA (insulin) ^{NR}	
	RELATED AGENTS		
	BYETTA (exenatide) SYMLIN (amylin)		
HYPOGLYCEMICS, MEGLITINIDES <i>Effective 4/2/07</i>	STARLIX (nateglinide)	PRANDIN (repaglinide)	The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.
HYPOGLYCEMICS, TZDS <i>Effective 4/2/07</i>	THIAZOLIDINEDIONES		
	ACTOS (pioglitazone) AVANDIA (rosiglitazone)		
	TZD COMBINATIONS		
	ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

INTRANASAL RHINITIS AGENTS <i>Effective 10/2/06</i>	ANTICHOLINERGICS		All of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
		ATROVENT (ipratropium) ipratropium	
	ANTIHISTAMINES		
	ASTELIN (azelastine)		
	CORTICOSTEROIDS		
	FLONASE (fluticasone) NASACORT AQ (triamcinolone) NASONEX (mometasone)	BECONASE AQ (beclomethasone) flunisolide fluticasone NASALIDE (flunisolide) NASAREL (flunisolide) RHINOCORT AQUA (budesonide)	
LEUKOTRIENE RECEPTOR BLOCKERS <i>Effective 10/2/06</i>	ACCOLATE (zafirlukast) SINGULAIR (montelukast)	ZYFLO (zileuton)	
LIPOTROPICS, OTHER (non-statins) <i>Effective 4/2/07</i>	BILE ACID SEQUESTRANTS		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If patients are on other statins and require the addition of Zetia, patients will not be required to switch the statin that they have been using.
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (cholesevalam)	
	CHOLESTEROL ABSORPTION INHIBITORS		
		ZETIA (ezetimibe)	
	FATTY ACIDS		
		OMACOR (omega-3-acid ethyl esters)	
	FIBRIC ACID DERIVATIVES		
	fenofibrate gemfibrozil TRICOR (fenofibrate)	ANTARA (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
	NIACIN		
	niacin NIASPAN (niacin)	NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL - Requires Clinical PA

NR - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

LIPOTROPICS, STATINS <i>Effective 4/2/07</i>	STATINS		One of the preferred statins must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin simvastatin	MEVACOR (lovastatin) PRAVACHOL (pravastatin) pravastatin ZOCOR (simvastatin)	
	STATIN COMBINATIONS		
	ADVICOR (lovastatin/niacin) VYTORIN (ezetimibe/simvastatin)	CADUET (atorvastatin/amlodipine)	
MACROLIDES/KETOLIDES (Oral) <i>Effective 10/2/06</i>	MACROLIDES		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	azithromycin BIAXIN XL (clarithromycin) erythromycin (base, ethylsuccinate, stearate)	BIAXIN (clarithromycin) clarithromycin DYNABAC (dirithromycin) E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	
	KETOLIDES		KETEK (telithromycin)
MULTIPLE SCLEROSIS AGENTS^{CL} <i>Effective 4/2/07</i>	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) REBIF (interferon beta-1a)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

NSAIDS <i>Effective 10/2/06</i>	NONSELECTIVE		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	diclofenac	ADVIL (ibuprofen)	
	etodolac	ANAPROX (naproxen)	
	fenoprofen	ANSAID (flurbiprofen)	
	flurbiprofen	CATAFLAM (diclofenac)	
	ibuprofen (Rx and OTC)	CLINORIL (sulindac)	
indomethacin	DAYPRO (oxaprozin)		
ketoprofen	FELDENE (piroxicam)		
ketorolac	INDOCIN (indomethacin)		
naproxen (Rx only)	LODINE (etodolac)		
oxaprozin	meclofenamate		
piroxicam	MOTRIN (ibuprofen)		
PONSTEL (meclofenamate)	nabumetone		
sulindac	NALFON (fenoprofen)		
tolmetin	NAPRELAN (naproxen)		
	NAPROSYN (naproxen)		
	NUPRIN (ibuprofen)		
	ORUDIS (ketoprofen)		
	VOLTAREN (diclofenac)		
NSAID/GI PROTECTANT COMBINATIONS			
	ARTHROTEC (diclofenac/misoprostol)		
	PREVACID NAPRAPAC (naproxen/lansoprazole)		
COX-II SELECTIVE^{CL}			
	CELEBREX (celecoxib)		
	meloxicam		
	MOBIC (meloxicam)		
		COX-II selective NSAIDs will be approved for patients with a GI Risk Score of ≥ 13 .	
OPHTHALMIC ANTIBIOTICS <i>Effective 10/2/06</i>	FLUOROQUINOLONES		All of the preferred agents must be tried before non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	VIGAMOX (moxifloxacin)	ciprofloxacin CILOXAN (ciprofloxacin) OCUFLOX (ofloxacin) ofloxacin QUIXIN (levofloxacin) ZYMAR (gatifloxacin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07**

Version 2007.2

	OTHER SINGLE AGENTS		
	bacitracin erythromycin gentamicin sulfacetamide tobramycin	BLEPH-10 (sulfacetamide) GENOPTIC (gentamicin) TOBEX (tobramycin)	
	COMBINATION AGENTS		
	neomycin/polymyxin/bacitracin neomycin/polymyxin/gramicidin polymyxin/bacitracin polymyxin/trimethoprim	NEOSPORIN (neomycin/polymyxin/bacitracin) NEOSPORIN (neomycin/polymyxin/gramicidin) POLYSPORIN (polymyxin/bacitracin) POLYTRIM (polymyxin/trimethoprim)	
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS <i>Effective 10/2/06</i>	ACULAR (ketorolac) ALREX (loteprednol) cromolyn ELESTAT (epinastine) OPTIVAR (azelastine) PATANOL (olopatadine)	ALOCRI (nedocromil) ALAMAST (pemirolast) ALOMIDE (lodoxamide) CROLOM (cromolyn) EMADINE (emedastine) ketotifen OPTICROM (cromolyn)	All of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS <i>Effective 10/2/06</i>	PARASYMPATHOMIMETICS		Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine	ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
	SYMPATHOMIMETICS		
	ALPHAGAN P (brimonidine) brimonidine dipivefrin	ALPHAGAN (brimonidine) PROPINE (dipivefrin)	
	BETA BLOCKERS		
	BETIMOL (timolol) BETOPTIC S (betaxolol) betaxolol carteolol levobunolol metipranolol timolol	BETAGAN (levobunolol) ISTALOL (timolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

	CARBONIC ANHYDRASE INHIBITORS		
	AZOPT (brinzolamide) TRUSOPT (dorzolamide)		
	PROSTAGLANDIN ANALOGS		
	LUMIGAN (bimatoprost) TRAVATAN (travoprost)	XALATAN (latanoprost)	
	COMBINATION AGENTS		
	COSOPT (dorzolamide/timolol)		
OTIC FLUOROQUINOLONES <i>Effective 4/2/07</i>	CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)	CIPRO HC (ciprofloxacin/hydrocortisone)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PHOSPHATE BINDERS <i>Effective 4/2/07</i>	FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)		
PLATELET AGGREGATION INHIBITORS <i>Effective 10/2/06</i>	AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)	dipyridamole PERSANTINE (dipyridamole) TICLID (ticlopidine) ticlopidine	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PROTON PUMP INHIBITORS (Oral) <i>Effective 4/2/07</i>	NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole)	ACIPHEX (rabeprazole) omeprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)	The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Prior authorization is not required for Prevacid Solu-Tabs through age 8.
SEDATIVE HYPNOTICS <i>Effective 4/2/07</i>	BENZODIAZEPINES		
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam	The preferred agent must be tried for 14 days before a non-preferred agent will be authorized unless one of the exceptions of the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.2

REVISED 6/13/07
Implementation Date: 4/02/07
Originally Posted: 3/15/07

	OTHERS		
	AMBIEN (zolpidem) AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon)		
STIMULANTS AND RELATED AGENTS <i>Effective 10/2/06</i>	AMPHETAMINES	Except for Strattera, PA is required for adults >18 years. One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized. Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants. Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy. Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period.	
	ADDERALL XR (amphetamine salt combination) amphetamine salt combination dextroamphetamine		ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) DEXTROSTAT (dextroamphetamine)
	NON-AMPHETAMINE		DAYTRANA (methylphenidate) ^{NR} METADATE ER (methylphenidate) pemoline PROVIGIL (modafanil) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN-SR (methylphenidate)
ULCERATIVE COLITIS AGENTS <i>Effective 4/2/07</i>	ORAL	The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.	
	ASACOL (mesalamine) COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) Sulfasalazine		AZULFIDINE (sulfasalazine)
	RECTAL		CANASA (mesalamine) mesalamine
	ROWASA (mesalamine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee